US Market News
3日前
Owlet Announces New $25 Million Credit Facility with Wells Fargo, Significantly Reducing Borrowing Costs and Enhancing Financial FlexibilityJune 30, 2026 4:15 PM
Business WireOwlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced that it has entered into a new $25 million asset-based revolving credit facility on June 26, 2026, with Wells Fargo Bank, National Association (“Wells Fargo”). The new facility refinances and replaces the Company’s existing asset-based credit facility and term loan, significantly reducing Owlet’s cost of capital, enhancing liquidity, and providing increased financial flexibility to support future operating and strategic initiatives. The improved terms reflect the Company's stronger financial position and continued operational execution.The new revolving credit facility lowers the applicable interest rate margin to SOFR plus 2.00% to 2.25%, compared to SOFR plus 7.50% to 8.50% under the Company’s previous asset-based facility, significantly reducing borrowing costs by at least 525 basis points. Following the closing of the refinancing, the Company’s total liquidity, consisting of cash and cash equivalents and available borrowing capacity under the facility, was approximately $33.8 million as of June 26, 2026.“Our new credit facility with Wells Fargo marks another important milestone in Owlet’s financial evolution,” said Amanda Twede Crawford, Chief Financial Officer of Owlet. “By replacing our previous debt structure with a more flexible revolving facility, we expect to meaningfully lower annual interest expense while enhancing liquidity and financial flexibility. The support from Wells Fargo positions us to continue investing in our strategic priorities while maintaining a disciplined approach to capital allocation.”“We are pleased to support Owlet as it continues to execute on its growth strategy and we look forward to continuing our relationship,” said Andy Hay, Executive Director, Wells Fargo.The new facility provides up to $25 million of borrowing capacity and includes the ability to increase commitments to as much as $35 million, subject to lender approval. The facility matures three years from closing.About Owlet, Inc.Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere.Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life.Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expected total liquidity, available borrowing capacity and access to capital under the new credit facility; the expected reduction in annual interest expense; the anticipated enhancement of the Company’s liquidity and financial flexibility; and the Company’s ability to pursue operational and strategic priorities while maintaining a disciplined approach to capital allocation. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “continues,” “designed,” “seek,” “will,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to: (i) the commercial success of Owlet’s products, including its subscription services; (ii) the extent to which the refinancing reduces borrowing costs, enhances liquidity and provides increased financial flexibility to support future operations and strategic initiatives; (iii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA, the TGA and other similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and comply with ongoing regulatory requirements; (iv) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (v) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (vi) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy, data protection and cybersecurity, including for Owlet’s digital platforms and technologies; (vii) Owlet’s ability to maintain relationships with channel partners, customers, manufacturers and suppliers; (viii) impacts from compliance with applicable laws or regulations; (ix) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (x) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xi) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.View source version on businesswire.com: https://www.businesswire.com/news/home/20260630032929/en/Investor Relations: ir@owletcare.comMedia: pr@owletcare.com Original: Owlet Announces New $25 Million Credit Facility with Wells Fargo, Significantly Reducing Borrowing Costs and Enhancing Financial Flexibility
US Market News
2月前
Owlet Expands ANZ Product Suite with Launch of Dream Sight™ and Dream Duo™ 3, Bringing the World’s Most Comprehensive Baby Monitoring System to More FamiliesMay 11, 2026 7:00 PM
Business Wire Following a successful Dream Sock® launch, Owlet now offers its full award-winning monitoring ecosystem in ANZ — combining medically-certified health tracking with 2K HD video and the industry’s most advanced cybersecurity protections. Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced the launch of Dream Sight and Dream Duo 3 across Australia and New Zealand. The expansion builds on the Company’s 2025 Dream Sock launch and brings Owlet’s full lineup of award-winning baby monitoring products to ANZ families for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511586578/en/Named ‘Best for Monitoring Baby’s Health’ in the PARENTS 2026 Best for Baby Awards, Owlet Dream Duo 3 delivers a view of the baby’s wellness, sleep, and environment. Now available in ANZ. “When we launched Dream Sock in Australia and New Zealand late last year, the response from local families was extraordinary,” said Kurt Workman, Owlet’s President, Chief Executive Officer, and Co-Founder. “We are proud to give even more parents access to our smartest, most comprehensive monitors to date, and continue to build upon our vast set of infant sleep and health data.” A Complete Monitoring Ecosystem, Now in ANZ With this launch, Australian and New Zealand families can access Owlet’s full ecosystem of products: Dream Sock: With clearance from Australia’s Therapeutic Goods Administration (TGA), and FDA clearance, the Company’s wearable smart baby monitor tracks pulse rate and oxygen level for infants 0–18 months, with real-time alerts sent directly to parents, and also provides sleep trends. Dream Sight: An all-new, premium 2K HD video baby monitor with night vision, a 130-degree wide-angle lens, two-way talk, automatic video clip capture, motion, sound, and cry detection, and temperature and humidity monitoring. Protected by 256-bit encryption and industry-leading anti-hacking technology, Dream Sight is the only baby monitor awarded the SGS Cybersecurity Mark. Dream Duo 3: Owlet’s most comprehensive baby monitoring system, combining Dream Sock and Dream Sight. Named ‘Best for Monitoring Baby’s Health’ in the PARENTS 2026 Best for Baby Awards, Dream Duo 3 delivers a view of the baby’s wellness, sleep, and environment. All products integrate with the free Owlet Dream App (iOS and Android) for real-time health readings, smart alerts, and sleep trends. Families seeking deeper insights can subscribe to Owlet360™, which adds daily sleep reports, expanded trend analytics, extended video storage, comparative sleep data, and more. Trusted by more than 2.5 million families around the globe, Owlet’s platform has generated a large and unique collection of pediatric health and sleep data. Parents who use Owlet monitors report meaningful outcomes: 96% of Owlet sock users have reported feeling less anxiety, and 94% have reported better quality of sleep.* Dream Sight, Dream Duo 3, and Dream Sock are available now in Australia and New Zealand through Owlet’s local e-commerce website at www.owletcare.com.au and select retail partners. *Based on a 2017 survey of 5,125 users of Owlet Smart Sock (Dangerfield et al., Global Pediatric Health, 2017). Results are self-reported and may not be representative of all users. About Owlet, Inc. Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the anticipated launch, availability, market acceptance, adoption, capabilities, and performance of the Company’s products and services in Australia and New Zealand, the expected benefits and features of such products and services, product enhancements, growth prospects, regulatory clearances, approvals, certifications and classifications, subscription offerings and related services, and the Company’s strategic initiatives, growth strategies and product development efforts. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “continues,” “designed,” “seek,” “will,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to: (i) the commercial success of Owlet’s products, including its subscription services, and the Company’s ability to support, scale and maintain its subscription services; (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA, the TGA and other similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and comply with ongoing regulatory requirements; (iii) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (iv) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (v) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy, data protection and cybersecurity, including for Owlet’s digital platforms and technologies; (vi) Owlet’s ability to maintain relationships with channel partners, customers, manufacturers and suppliers; (vii) impacts from compliance with applicable laws or regulations; (ix) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (x) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xi) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties. View source version on businesswire.com: https://www.businesswire.com/news/home/20260511586578/en/ Owlet Media Contacts:
pr@owletcare.com
owlet@hannahcranstonmedia.com Owlet Investor Contact:
ir@owletcare.com Original: Owlet Expands ANZ Product Suite with Launch of Dream Sight™ and Dream Duo™ 3, Bringing the World’s Most Comprehensive Baby Monitoring System to More Families
US Market News
2月前
Owlet Gives Moms the Ultimate Mother's Day Gift: More Confidence and Peace of MindMay 4, 2026 8:50 AM
Business Wire
Two weeks of savings from the maker of FDA-cleared Dream Sock®, plus exclusive direct-to-consumer offers from Divi Growth Care™ to support every part of mom's postpartum journey.
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today shared its 2026 Mother’s Day campaign, which aims to support moms and give them more confidence. The two-week campaign encourages moms to let Owlet do more with steep discounts on its products and a new, exclusive partnership with Divi, the Growth Care™ brand founded by Dani Austin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504599378/en/This Mother's Day, Owlet has partnered with Divi, the Growth Care™ brand founded by Dani Austin, to support moms through every part of the postpartum journey. Shop the exclusive partnership at www.owletcare.com.
Doing More for Moms
New mothers sleep an average of just 4.4 hours per night during the first week postpartum, and sleep discontinuity remains an ongoing issue. According to Owlet’s State of Parenting Report, even when the baby rests, many parents wake frequently throughout the night to check on their infant.
Owlet’s award-winning technology was built to address that specific experience, designed to help new parents sleep more peacefully by tracking their baby’s pulse rate and oxygen levels with clinically-validated accuracy. More than 2.5 million families worldwide have turned to Owlet for reassurance, and 96% of Owlet sock users have reported feeling less anxiety, and 94% have reported better quality of sleep.*
“Mother's Day is often treated as a gifting moment, but for most new moms, what they actually need is more and better rest. We believe Owlet gives moms the confidence and peace of mind they deserve," said Liz Teran, Chief Parent Officer at Owlet. “This year, we’re bringing that to life by empowering moms to let us do more for them so they can focus on what matters most, and we’re excited to partner with Divi to give moms something extra just for them to support their recovery and postpartum journey.”
Something Extra for Mom: A Gift from Divi
Owlet is offering its discounted products for Mother’s Day, along with something new: a gift-with-purchase from Divi and an exclusive Owlet x Divi bundle. In one study, over 90% of women reported experiencing postpartum hair loss, yet it’s rarely part of the broader conversation around recovery. Divi tackles this through its Growth Care™ philosophy, providing Complete Care for Growing Hair™, a system designed to promote and protect strands for fuller, thicker, stronger, healthier-looking hair over time. Owlet and Divi share a belief that caring for a new mother means looking at the full picture and giving moms the tools to empower confidence and feel their best.
"Becoming a mom means pouring so much of yourself into this tiny person you love and somewhere in all of that, it's so easy to lose sight of you," said Dani Austin, Founder of Divi. "I've lived that, and it's why this partnership with Owlet feels so personal. Owlet gives moms peace of mind when it matters most, and at Divi, we're right there with them, helping moms feel like themselves again through small, doable self-care rituals that actually stick. Together, through this partnership, we get to show up for mamas through every season of motherhood.”
As part of this partnership, Owlet and Divi will make a donation of 30 care packages to Intermountain Primary Children's Hospital, located in Salt Lake City, Utah. The care packages will go directly to moms who are celebrating their first Mother’s Day while navigating the challenges of having a baby in the NICU.
The Full Lineup, On Sale
Owlet’s Mother’s Day campaign features promotional pricing across its infant monitoring ecosystem, plus exclusive Divi offers:
$60 off Dream Sock®: The FDA-cleared wearable that tracks pulse rate and oxygen levels, and gives parents an overview of their baby’s sleep patterns.
$80 off Dream Duo™ 3: Owlet’s all-in-one solution combining the Dream Sock with an integrated HD camera for comprehensive monitoring.
$20 off Dream Sight™: Advanced HD video monitoring with smart notifications, streamlined wall-mount design, and room environment tracking.
May 3-9: Promotional pricing on all qualifying Owlet products, plus a free Divi 30mL Scalp Serum ($48 value) included with every Dream Sock or Dream Duo 3 purchase at www.owletcare.com only.
May 10-17: Campaign pricing continues, with an exclusive Dream Duo 3 + Divi Best Sellers bundle available only at www.owletcare.com for $349.99 (savings of more than $100).
Owlet’s Mother’s Day offers are available May 3-17, 2026, at www.owletcare.com and at leading retailers, including Walmart, Amazon, Babylist, Target, Best Buy, and more. Exclusive gifts with purchase and bundles are only available at www.owletcare.com (U.S. only, while supplies last; exclusions may apply).
*Based on a 2017 survey of 5,125 users of Owlet Smart Sock (Dangerfield et al., Global Pediatric Health, 2017). Results are self-reported and may not be representative of all users.
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.
About Divi
Founded in 2021 by creator and entrepreneur Dani Austin, Divi is a hair health and wellness brand pioneering Growth Care™—Complete Care for Growing Hair™. Inspired by Dani’s personal hair loss journey, Divi was created for women experiencing thinning, shedding, and changing hair at every stage of life. The brand develops science-backed formulas designed to promote healthier-looking hair by addressing both internal and external factors that impact hair over time. Divi’s lineup includes its new Hair Growth Vitamins, award-winning Scalp Serum, Dry Shampoo, and Shampoo and Conditioner collections—each formulated to support stronger, fuller-looking hair as part of a consistent daily routine. Beyond products, Divi cultivates a supportive community rooted in transparency, education, and real results. For more information about Divi and Growth Care™, visit www.diviofficial.com or follow Divi on Instagram @diviofficial and TikTok @official.divi. To get to know our founder, follow @daniaustin.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s Mother’s Day campaign and associated promotional pricing; the expected duration and availability of product discounts and bundles; the anticipated benefits and goals of the Company’s partnership with Divi; the Company’s planned charitable donations; and expected consumer response to the Company’s products and partnerships. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “continues,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to: (i) the commercial success of Owlet’s products, including its subscription services, and the Company’s ability to support, scale and maintain its subscription services; (ii) the adoption, implementation, and effectiveness of employer-based programs, including Owlet for Orgs, and the willingness of employers to offer such programs to their employees; (iii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and comply with ongoing regulatory requirements; (iv) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information, and risks of cybersecurity incidents or changes in applicable standards or interpretations; (v) the performance of, and Owlet’s ability to maintain and expand, its relationship with third-party technology, cloud, manufacturing and distribution partners; (vi) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vii) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (viii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (ix) Owlet’s ability to maintain relationships with channel partners, customers, manufacturers and suppliers; (x) the effectiveness of the Company’s marketing, public relations, and communications strategies, and the ability of such strategies to generate consumer and investor interest and improve brand awareness and discoverability; (xi) impacts from compliance with applicable laws or regulations; (xii) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xiii) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xiv) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260504599378/en/
Owlet Media Contacts:
pr@owletcare.com
owlet@hannahcranstonmedia.com
Owlet Investor Contact:
ir@owletcare.com
Divi Contact:
Divi@paulstreet.co
Original: Owlet Gives Moms the Ultimate Mother's Day Gift: More Confidence and Peace of Mind
US Market News
3月前
Owlet Launches New Employer Benefit Program, Empowering Companies to Support Parents with Medical-Grade Infant Health MonitoringApril 16, 2026 8:45 AM
Business Wire
VGM Group Joins as Inaugural Employer Partner, Championing Family Well-Being as Owlet Expands Access to its FDA-Cleared Infant Wearable Technology
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced the launch of Owlet for Orgs, a new employer benefit program that enables companies to provide new and expecting parents with its trusted infant health technology. Owlet is proud to announce VGM Group, Inc., a 100% employee-owned company providing business and professional services to thousands of business customers across North America, as its inaugural employer partner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260416143201/en/
Through Owlet for Orgs, employers can now provide Owlet baby monitors as part of a customized workplace benefits package for new and expecting parents. Employers can select FDA-cleared Dream Sock®, which tracks pulse rate and oxygen levels, or Dream Duo™ 3, which includes Dream Sock and all-new Dream Sight™ video monitor. By providing clinically-validated monitoring technology, employers can support staff through one of life's most significant transitions by helping to promote better peace of mind at home, while contributing to stronger employee loyalty and retention. Owlet partners directly with human resources and benefits teams to tailor the program to each organization and support a smooth rollout.
"Early parenthood is easily one of the most overwhelming seasons of a person's life, and businesses that can acknowledge and support that are building stronger, more loyal teams," said Liz Teran, Chief Parent Officer at Owlet. "Owlet for Orgs gives companies a way to show up for their employees when it matters most, with more than just policy on paper. We're proud to launch this program, and we expect to expand our partners for this program in the months ahead.”
VGM Group is a 100% employee-owned company with a track record of supporting working parents. In 2023, it opened an on-site child care center at its headquarters in Waterloo, Iowa, in response to employee owners' challenges finding reliable, affordable child care. This focus on supporting working parents and community well-being aligns with Owlet's mission to support pediatric wellness, and it has earned VGM Group recognition as an Iowa Top Workplace and a Best Place for Working Parents.
"At VGM Group, caring for our employee owners means caring for the people who matter most to them," said Sara Laures, VGM Group Chief People Officer. "Along with benefits like our on-site child care center and free health clinic, Owlet for Orgs is another way we're investing in our people during one of life's most meaningful times. When new parents feel supported and confident in their baby's well-being, we believe it creates more peace of mind at home and enables them to stay engaged at work."
The launch of Owlet for Orgs advances the Company’s goal to give families more clarity, confidence, and peace of mind. The program expands access to Owlet's ecosystem of clinically-validated products, among them the first and only FDA-cleared baby monitor on the market, Dream Sock. The Company also offers an insurance-supported prescription pulse oximeter, BabySat®. Via its advocacy arm, Owlet Cares, the Company works with 40+ nonprofit organizations across the globe to provide products, resources, and safe sleep education to families. Owlet for Orgs is the next natural step, extending that same ecosystem of care beyond the home and into the broader network of professionals and organizations that families trust.
Employers interested in bringing Owlet for Orgs to their workforce can learn more and connect with the Owlet team at www.owletcare.com/pages/employer-benefits.
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.
About VGM Group
Headquartered in Waterloo, Iowa, VGM is a 100% employee-owned company providing business and professional services to thousands of business customers across North America. Services include group purchasing, commercial insurance, management of healthcare services and networks in post-acute cases, healthcare distribution direct to patient homes, specialty consulting, and online education, as well as digital, print, and traditional marketing and more. VGM employs approximately 1,600 people across 42 states and Canada, with more than 1,100 working in Iowa. VGM has been named the Top Workplace in Iowa, Employer of Choice, and Best Place for Working Parents on multiple occasions and is proud of its role in the communities in which it serves. For more information visit www.vgmgroup.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the expected benefits and adoption of the Owlet for Orgs program, including employer adoption, employee utilization, and perceived value of such programs; the Company’s ability to expand employer partnerships and distribution channels; the anticipated impact of the program on employee engagement, retention, and satisfaction; the Company’s ability to scale and support its products, services and subscription offerings; and the Company’s expectations regarding future growth, market expansion, product development, and commercialization. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “continues,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to: (i) the commercial success of Owlet’s products, including its subscription services, and the Company’s ability to support, scale and maintain its subscription services; (ii) the adoption, implementation, and effectiveness of employer-based programs, including Owlet for Orgs, and the willingness of employers to offer such programs to their employees; (iii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and comply with ongoing regulatory requirements; (iv) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information, and risks of cybersecurity incidents or changes in applicable standards or interpretations; (v) the performance of, and Owlet’s ability to maintain and expand, its relationship with third-party technology, cloud, manufacturing and distribution partners; (vi) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vii) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (viii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (ix) Owlet’s ability to maintain relationships with channel partners, customers, manufacturers and suppliers; (x) the effectiveness of the Company’s marketing, public relations, and communications strategies, and the ability of such strategies to generate consumer and investor interest and improve brand awareness and discoverability; (xi) impacts from compliance with applicable laws or regulations; (xii) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xiii) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xiv) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260416143201/en/
Owlet Media Contacts:
pr@owletcare.com
owlet@hannahcranstonmedia.com
Owlet Investor Contact:
ir@owletcare.com
VGM Group Contact:
Christa Miehe, Chief Communications Officer
christa.miehe@vgm.com
Original: Owlet Launches New Employer Benefit Program, Empowering Companies to Support Parents with Medical-Grade Infant Health Monitoring
US Market News
3月前
Owlet Dream Duo™ 3 Named 'Best for Monitoring Baby's Health' in PARENTS 2026 Best for Baby AwardsApril 7, 2026 1:31 PM
Business Wire
The Only Pediatric Health Platform Pairing an FDA-Cleared Infant Wearable with a Cybersecurity-Certified Video Monitor Earns Top Recognition from Editors and Expert Testers
Owlet, Inc. (NYSE: OWLT), the pioneer of smart infant monitoring, today announced that Dream Duo 3 is named ‘Best for Monitoring Baby's Health’ in the PARENTS 2026 Best for Baby Awards. The recognition underscores Owlet’s position as a leader in connected infant monitoring, providing clinically-informed wellness and sleep insights.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407055415/en/Owlet Dream Duo 3 wins ‘Best for Monitoring Baby's Health’ in the PARENTS 2026 Best for Baby Awards.
The PARENTS Best for Baby Awards is the definitive guide to the best new baby gear, as well as the top products designed to help caretakers during pregnancy and beyond. PARENTS editors carefully vet and review hundreds of products, enlisting industry experts and real-world parent testers to evaluate each on safety, durability, effectiveness, and ease of use.
Dream Duo 3 pairs two category-defining products into one seamless platform:
Dream Sock®, the first and only FDA-cleared over-the-counter baby monitor, tracks pulse rate, oxygen levels, and sleep patterns in real-time.
Dream Sight™, the only baby monitor awarded the SGS Cybersecurity Mark, offers 2K HD video, night vision, and room temperature and humidity monitoring, so parents can see and understand their baby's environment at a glance.
Together, they go far beyond what traditional monitors offer. Rather than capturing sound or motion alone, Dream Duo 3 transforms data into personalized, actionable intelligence, helping families better understand their baby’s sleep patterns, routines, and wellness trends over time. Real Owlet parents describe the difference in their own words. Nicole E., an Owlet user, put it simply: "On nights when he was coming down with a cold, or when he wasn't getting the best rest, Owlet gave us the insight we needed to take better care of him. It's truly been more than just a product; it's been a reassuring presence through the ups and downs of our first year."
"Dream Duo 3 was built to give parents the same quality of insight for their babies that wearable health technology has already given them for themselves," said Liz Teran, Chief Parent Officer at Owlet. "Being recognized by PARENTS reflects the trust that families and experts have placed in this technology and the standard we hold ourselves to every time we build something new. We’re honored to be named to this prestigious award list."
Trusted by more than 2.5 million families, Owlet's platform has fueled one of the largest pediatric health datasets in the world. Dream Duo 3 is part of a broader Owlet ecosystem designed to support every family and every baby, including prescription-only BabySat® for higher-acuity monitoring needs, and Owlet360™, a subscription service delivering deeper insights over time, turning daily data into a longitudinal picture of your baby's well-being.
Dream Duo 3 is available at www.owletcare.com, and major retailers across the globe, including Walmart, Amazon, Babylist, Target, John Lewis, and more. The full list of PARENTS 2026 Best for Baby Award winners is available at https://www.parents.com/parents-2026-best-for-baby-awards-11938008.
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, expectations regarding the features, performance, functionality, consumer experience, commercial availability, market reception and potential benefits of Dream Duo 3, Dream Sight, Dream Sock, Owlet360 and the broader Owlet ecosystem, as well as statements regarding the significance of industry recognition, consumer adoption, and the Company’s ability to support families through its products and services. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “continues,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to: (i) the commercial success of Owlet’s products, including its subscription services, and the Company’s ability to support, scale and maintain its subscription services; (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and comply with ongoing regulatory requirements; (iii) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information, and risks of cybersecurity incidents or changes in applicable standards or interpretations; (iv) the performance of, and Owlet’s ability to maintain and expand, its relationship with third-party technology, cloud, manufacturing and distribution partners; (v) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vi) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (vii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (viii) Owlet’s ability to maintain relationships with channel partners, customers, manufacturers and suppliers; (ix) the effectiveness of the Company’s marketing, public relations, and communications strategies, and the ability of such strategies to generate consumer and investor interest and improve brand awareness and discoverability; (x) impacts from compliance with applicable laws or regulations; (xi) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xii) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xiii) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. The Company operates in a rapidly evolving regulatory, technological and consumer environment, and new risks and uncertainties may emerge from time to time, including those related to product performance, consumer usage, regulatory interpretation, data privacy and security, and competitive offerings, and it is impossible for the Company to predict all such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260407055415/en/
Owlet Media Contacts:
pr@owletcare.com
owlet@hannahcranstonmedia.com
Owlet Investor Contact:
ir@owletcare.com
Original: Owlet Dream Duo™ 3 Named 'Best for Monitoring Baby's Health' in PARENTS 2026 Best for Baby Awards
US Market News
3月前
Owlet Announces CEO Transition; Board Reaffirms Q1 2026 Guidance and Long-Term Growth OpportunityApril 6, 2026 4:05 PM
Business Wire
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, announced today that Jonathan Harris has resigned as President and Chief Executive Officer, effective immediately. The Board thanks Jonathan for his leadership and dedicated service to the Company and families worldwide.
Kurt Workman, current Executive Chair of the Board, co-founder, and former CEO, will rejoin as President and Chief Executive Officer to lead the Company and execution of its strategic priorities. Kurt will cease serving as Executive Chairman of the Board, but will remain a director of the Board.
“I’m incredibly excited to have Kurt back in the CEO role. His strategic vision for the future of Owlet and his demonstrated ability to effectively execute on that vision make him uniquely qualified for the CEO role as we enter this next chapter of the business. The Board and I welcome his energy and commitment to leading the Owlet team as we solidify our leadership position as partners to the next generation of families, globally,” said Lior Susan, Owlet’s Chairman of the Board.
Financial Update
Owlet expects to be at the high end of its Q1 2026 revenue guidance range.
Owlet will report Q1 2026 financial results and business outlook in early May 2026. The Company remains committed to profitability, driven by revenue growth, continued expense discipline, and a focus on operational excellence.
Owlet reaffirms its long-term strategic pillars of increasing adoption, expanding LTV, and leveraging Owlet’s vast and growing data set to create the pediatric health platform parents need for their children.
Reinforcing this commitment to the Company’s long-term plan, Owlet also announced today that Chief Financial Officer, Amanda Twede Crawford, has elected to receive 100% of her 2025 annual bonus in Owlet common stock in lieu of cash.
“My return as CEO is a commitment to the mission I started in a garage 12 years ago,” said Kurt Workman. “Owlet is the category leader in pediatric health monitoring with an unparalleled data set, yet there is still an immense opportunity to increase our market penetration, accelerate adoption and improve the health and wellness of infants worldwide. I am stepping back in to deliver on this vision. My goal is to make Owlet the standard for at-home pediatric health, and I’m ready to get back to work with this incredible team, our amazing partners and the parents around the world that put their faith and trust in the Owlet brand.”
Financial Disclosure Advisory
This press release contains certain estimated preliminary financial results for the first quarter ended March 31, 2026. These estimates are based on the information available to the Company at this time. The Company’s financial closing and procedures for the first quarter of fiscal 2026 are not yet complete and, as a result, actual results may vary from the estimated preliminary results presented here. The estimated preliminary financial results have not been audited or reviewed by the Company’s independent registered public accounting firm. These estimates should not be viewed as a substitute for the Company’s full interim financial statements. Accordingly, you should not place undue reliance on this preliminary financial information.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company's expected financial performance, including the Company's financial outlook and reaffirmation of previously issued guidance, the anticipated benefits of the Company's leadership transition, the Company's long-term strategic priorities and business strategy, including plans related to market penetration, user growth and scaling of the Company's subscription model, leveraging the Company's data to build its pediatric health platform, product enhancements, growth prospects, future operational results, and expected market opportunity and acceptance. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for our products and other regulatory requirements and legal proceedings; (ii) Owlet’s competition and the Company’s ability to achieve future growth and sustain its growth rate; (iii) Owlet’s ability to attract and retain customers and increase sales to its customers; and (iv) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as any such factors may be updated from time to time in the Company’s other filings with the SEC. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260406627177/en/
Owlet Media Contacts:
pr@owletcare.com
owlet@hannahcranstonmedia.com
Owlet Investor Contact:
ir@owletcare.com
Original: Owlet Announces CEO Transition; Board Reaffirms Q1 2026 Guidance and Long-Term Growth Opportunity
US Market News
3月前
Owlet Joins Babylist to Donate Product to Children's Hospital Los Angeles in Support of Make March Matter CampaignMarch 26, 2026 8:51 AM
Business Wire
Donation Brings Owlet’s Medical-Grade Monitoring Technology Directly to Families in CHLA's Newborn Intensive Critical Care Unit
Owlet, Inc. (NYSE: OWLT), the pioneer of smart infant monitoring, joins Babylist in support of Children's Hospital Los Angeles (CHLA), one of the nation's top-ranked children's hospitals, and its 11th annual Make March Matter campaign benefiting critical pediatric care. The event, held at the Babylist Showroom in Beverly Hills, brings Owlet’s mission of giving every baby the best possible start in life directly to families who need it most.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326217261/en/Owlet joins Babylist in support of Children's Hospital Los Angeles and its 11th annual Make March Matter campaign. From left to right: Shawn Besabella, Babylist; Jillian Green, CHLA; Amanda Nelson, Owlet; Jamie Rahaeuser, Owlet; Dawn Wilcox Verrecchia, CHLA
Owlet's contribution encompasses $39,000 in product donations to CHLA's Newborn Intensive Critical Care Unit (NICCU), including Dream Sock® monitors, Dream Duo™ 3 bundles, and swaddles for NICCU families.
"The families in CHLA's NICCU are navigating some of the most overwhelming moments of their lives. Owlet offers them peace of mind by giving them a tool to bridge the hospital and the home," said Liz Teran, Chief Parent Officer at Owlet. "We are grateful to work with Babylist in support of Children's Hospital Los Angeles for this campaign. Make March Matter is a natural extension of everything we stand for at Owlet, and we're proud to put our products in the hands of the families who need them most.”
Make March Matter is CHLA's annual fundraising campaign, mobilizing individuals, families, and companies across the country to support the hospital's life-saving work. CHLA cares for children with the most complex and critical conditions, and its NICCU represents the frontline of that mission. Babylist, the leading baby registry and parenting resource, serves as a key campaign partner and hosted the March 24th event at its Beverly Hills Showroom.
"Helping families welcome their baby into the world is at the core of everything we do at Babylist, and our social impact work is no exception,” said Molly Goodson, VP of Brand & Media, Babylist. “We're so proud to host this event at our Showroom with the support of partners like Owlet, whose commitment to giving every baby the best possible start aligns so deeply with our own. Seeing Owlet's technology go directly into the hands of NICCU families through the care packages we assembled is exactly the kind of impact we set out to create in supporting Make March Matter."
Owlet's participation reflects the Company's commitment to health equity, ensuring that medical-grade infant monitoring technology reaches families facing the most acute need during their baby's earliest days. The Company's advocacy arm, Owlet Cares, has donated over $2.5 million in product and charitable support since 2021 and works with more than 40 global nonprofit partners to improve the lives of babies and families. Owlet is also actively working to expand insurance-supported access to FDA-cleared BabySat®, a prescription pediatric pulse oximeter, now available to TRICARE members and Medicaid families through its partnerships with durable medical equipment (DME) providers.
Dream Sock is the #1 smart baby monitor* and remains the first and only FDA-cleared over-the-counter infant wearable monitor on the market, while Dream Duo 3 pairs that clinical-grade monitoring with the Dream Sight™ smart video monitor in a single system. Used by more than 2.5 million families across 30+ countries to date, Owlet is building upon a vast pediatric health dataset and establishing a new standard for what infant care at home can look like.
For more information on Make March Matter, visit chla.org/makemarchmatter. To learn more about Owlet's products and mission, visit www.owletcare.com.
*Circana dollar share data; sourced 1/1/2025-12/31/2025
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding efforts to expand insurance-supported access to Babysat. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “continues,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to: (i) the commercial success of Owlet’s products, including its subscription services, and the Company’s ability to support, scale and maintain its subscription services; (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and comply with ongoing regulatory requirements; (iii) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information, and risks of cybersecurity incidents or changes in applicable standards or interpretations; (iv) the performance of, and Owlet’s ability to maintain and expand, its relationship with third-party technology, cloud, manufacturing and distribution partners; (v) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vi) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (vii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (viii) Owlet’s ability to maintain relationships with channel partners, customers, manufacturers and suppliers; (ix) the effectiveness of the Company’s marketing, public relations, and communications strategies, and the ability of such strategies to generate consumer and investor interest and improve brand awareness and discoverability; (x) impacts from compliance with applicable laws or regulations; (xi) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xii) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xiii) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260326217261/en/
Owlet Media Contacts:
pr@owletcare.com
owlet@hannahcranstonmedia.com
Owlet Investor Contact:
ir@owletcare.com
Original: Owlet Joins Babylist to Donate Product to Children's Hospital Los Angeles in Support of Make March Matter Campaign
US Market News
4月前
Owlet Reports Fourth Quarter and Full Year 2025 Results; Initiates 2026 GuidanceMarch 5, 2026 4:05 PM
Business Wire
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today reports financial results for the fourth quarter and full year ended December 31, 2025. Owlet’s President and Chief Executive Officer, Jonathan Harris, and Chief Financial Officer, Amanda Twede Crawford, will host a conference call to review the Company’s results and provide a business update today, March 5, 2026, at 4:30 p.m. ET.
Q4 2025 Financial Highlights:
Q4 Revenue of $26.6 million, up 29.6% from Q4 2024
Q4 Gross Profit of $12.6 million, up $1.7 million from Q4 2024 despite tariff cost impacts; Q4 Gross Margin of 47.6%
Q4 Operating Loss of $4.9 million, compared to operating loss of $7.4 million in Q4 2024
Q4 Net Loss of $9.2 million, compared to net loss of $9.1 million in Q4 2024
Q4 Adjusted EBITDA (non-GAAP) of $0.1 million, compared to $0.5 million in Q4 2024
Full Year 2025 Financial Highlights:
Record FY 2025 Revenue of $105.7 million, up 35.4% from FY 2024
Record FY 2025 Gross Profit of $53.5 million, up $14.2 million from FY 2024 despite tariff cost impacts; Record FY 2025 Gross Margin of 50.6%
FY 2025 Operating Loss of $8.3 million, compared to operating loss of $20.2 million in FY 2024
FY 2025 Net Loss of $39.7 million including a $26.6 million non-cash, mark-to-market common stock warrant liability adjustment, compared to net loss of $12.5 million in FY 2024
Record FY 2025 Adjusted EBITDA (non-GAAP) of $2.0 million, improving $3.8 million compared to FY 2024
“2025 was a defining chapter for Owlet, marked by record-breaking financial performance and a fundamental evolution into a comprehensive pediatric health, safety, and sleep platform,” said Jonathan Harris, Owlet’s President and CEO. “By delivering $105.7 million in revenue, the strongest in our history, alongside record gross margin and adjusted EBITDA results, we believe we have proven the scalability and resilience of our business model. Owlet’s financial and operational strength is the foundation enabling the next phase of our global growth, and long-term value creation for all of our stakeholders.”
Harris continued, “The launch of Owlet360™ subscription service has been a paradigm shift, deepening our relationship with parents and diversifying our long-term revenue streams. Surpassing 110,000 paying subscribers validates the value and trust families place in our connected ecosystem. When paired with the rollout of our AI-enabled Dream Sight™ camera, Owlet is much more than just a baby monitor brand — it is a sophisticated data platform establishing the gold standard for accurate infant biometric baselines from the first night.”
Harris concluded, “We enter 2026 ready to build on our momentum, and execute on our long-term growth opportunity. Owlet is well-positioned to leverage our unique pediatric dataset to redefine modern parenting and become the go-to wellness technology for families around the world.”
Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025
Fourth Quarter 2025 Results
Revenue for the fourth quarter of 2025 was $26.6 million compared to revenue in the fourth quarter of 2024 of $20.5 million, an increase of 29.6%. The increase was primarily due to higher sales of Dream product suite and Owlet360 subscription service.
Cost of revenue for the fourth quarter of 2025 was $13.9 million with a gross margin of 47.6%, compared to cost of revenue of $9.5 million with a gross margin of 53.5% for the fourth quarter of 2024. Gross margin decreased 596 basis points year-over-year, primarily reflecting tariff impacts, partially offset by favorable product mix, improved fixed cost absorption, lower direct and fulfillment costs, and growth in revenue for our Owlet360 subscription service.
Operating expenses, including stock-based compensation, were $17.5 million for the fourth quarter of 2025, compared to $18.4 million for the same period in 2024. Operating costs decreased year-over-year primarily due to a decrease in legal expenses, partially offset by increases in headcount related expenses, including salaries, bonus, benefits, and stock-based compensation.
Operating loss was $4.9 million for the fourth quarter of 2025, compared to operating loss of $7.4 million for the fourth quarter of 2024.
Net loss was $9.2 million for the fourth quarter of 2025, compared to net loss of $9.1 million for the fourth quarter of 2024.
Adjusted EBITDA (non-GAAP) was $0.1 million for the fourth quarter of 2025, compared to $0.5 million for the fourth quarter of 2024.
Net loss per share was $0.39 for the fourth quarter of 2025, compared to net loss per share of $0.63 for the fourth quarter of 2024. Adjusted net loss per share (non-GAAP) was $0.03 for the fourth quarter of 2025, compared to $0.07 for the same period in 2024.
Full Year 2025 Results
For fiscal year 2025, revenue was $105.7 million, compared to $78.1 million for fiscal year 2024, an increase of 35.4%.
Cost of revenue for the fiscal year 2025 was $52.2 million with a gross margin of 50.6%, compared to cost of revenue of $38.7 million with a gross margin of 50.4% for fiscal year 2024.
Operating expenses, including stock-based compensation, were $61.8 million for the fiscal year 2025, compared to $59.5 million for the same period in 2024.
Operating loss was $8.3 million for the fiscal year 2025, compared to operating loss of $20.2 million for the fiscal year 2024.
Net loss was $39.7 million for the fiscal year 2025, compared to net loss of $12.5 million for the fiscal year 2024.
Adjusted EBITDA (non-GAAP) was $2.0 million for the fiscal year 2025, compared to a loss of $1.8 million for the fiscal year 2024, an improvement of $3.8 million.
Net loss per share was $2.31 for the fiscal year 2025, compared to net loss per share of $1.57 for the fiscal year 2024. Adjusted net loss per share (non-GAAP) was $0.11 for the fiscal year 2025, compared to $0.36 for the same period in 2024.
2026 Financial Outlook
For the first quarter of 2026, we expect revenue in the range of $20 to $21 million, gross margins of 50% to 52%, and Adjusted EBITDA of $(2.5) to $(1.5) million.
For the full year 2026, we expect revenue in the range of $126 to $130 million, representing 19% to 23% growth over 2025, gross margins of 49% to 52% including the impact of tariff costs, and Adjusted EBITDA of $3 to $5 million, representing 50% to 150% growth over 2025.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expected financial performance, including the Company’s financial outlook, outlook based upon global regulatory clearances, approvals, certifications, and/or classifications, product enhancements, growth prospects, future operational efficiencies or results, and expected market opportunity and acceptance. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by our forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for our products and other regulatory requirements and legal proceedings; (ii) Owlet’s competition and the Company’s ability to achieve future growth and sustain its growth rate; (iii) Owlet’s ability to attract and retain customers and increase sales to its customers; (iv) Owlet’s ability to obtain additional financing in the future, as well risks associated with the Company’s current loan and debt agreements, including compliance with debt covenants, restrictions on the Company’s access to capital, the impact of the Company’s overall debt levels and the Company’s ability to generate sufficient future cash flows to meet Owlet’s debt service obligations and operate Owlet’s business; (v) the ability of Owlet to implement strategic initiatives, reduce costs, develop and launch new products, innovate and enhance existing products, scale its platform, meet customer demands and adapt to changes in consumer preferences and retail trends; (vi) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements, including but not limited to requirements concerning privacy and data protection, breaches and loss, as well as other risks associated with Owlet’s digital platforms and technologies; (vii) Owlet’s ability to maintain relationships with manufacturers and suppliers and retain Owlet’s management and key employees; (viii) Owlet’s ability to upgrade and maintain its information technology systems; (ix) changes in applicable laws or regulations in the United States and other jurisdictions; (x) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control, such as health epidemics or pandemics, macro-economic uncertainties, tariffs or trade restrictions, social unrest, hostilities, natural disasters or other catastrophic events; (xi) the possibility that Owlet may be adversely affected by other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xii) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as updated in the Company’s quarterly reports on Form 10-Q, as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties. The Company has not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. As a result, all financial results described in this earnings release should be considered preliminary, and are subject to change to reflect any necessary adjustments or changes in accounting estimates, that are identified prior to the time the Company files its Annual Report on Form 10-K.
Disclosure Regarding Non-GAAP Financial Measures
In addition to the financial measures presented in this release in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), the Company has included certain non-GAAP financial measures in this release, including adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share.
The Company uses such non-GAAP financial measures as internal measures of business operating performance and as performance measures for benchmarking against the Company’s peers and competitors. The Company believes its presentation of adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share provides a meaningful perspective of the underlying operating performance of the Company’s current business and enables investors to better understand and evaluate its historical and prospective operating performance. The Company believes that these non-GAAP financial measures are important supplemental measures of operating performance because they exclude items that vary from period to period without correlation to the Company’s core operating performance and highlight trends in its business that may not otherwise be apparent when relying solely on GAAP financial measures. Due to the nature of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of the Company’s future operating performance. The Company believes investors, analysts and other interested parties use adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share in evaluating issuers, and the presentation of these measures facilitates a comparative assessment of the Company’s operating performance in addition to the Company’s performance based on GAAP results.
The Company’s non-GAAP financial measures should not be considered as an alternative to net income (loss) or net income (loss) per share as a measure of financial performance or any other performance measure derived in accordance with GAAP and should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items.
Adjusted EBITDA is defined as net income (loss) adjusted for income tax provision, interest expense, net, depreciation and amortization, impairment of intangible assets, common stock warrant liability adjustment, stock-based compensation, transaction costs, charges related to certain legal matters, net of insurance loss recovery related to certain legal matters, and restructuring costs.
Adjusted net income (loss) is defined as net income (loss) adjusted for impairment of intangible assets, common stock warrant liability adjustment, stock-based compensation, transaction costs, insurance loss recovery related to certain legal matters, net of charges related to certain legal matters, and restructuring costs. Adjusted net income (loss) per share is defined as adjusted net income (loss) divided by the basic weighted-average number of shares of common stock outstanding.
Adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share are not recognized terms under GAAP, and the Company’s presentation of these non-GAAP measures does not replace the presentation of the Company’s financial results in accordance with GAAP. Because all companies do not use adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share (and similarly titled financial measures) in the same way, those measures as used by other companies may not be consistent with the way the Company calculates such measures. The non-GAAP financial measures included in this release should not be construed as substitutes for or better indicators of the Company’s performance than the most directly comparable GAAP financial measures. See the reconciliation tables that accompany this release for additional information regarding certain of the non-GAAP financial measures included herein.
A reconciliation of the Company's guidance contained in this press release with respect to non-GAAP financial measures to the most directly comparable GAAP financial measure cannot be provided without unreasonable efforts and is not provided herein because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, the amounts of which could be material.
Conference Call and Webcast Information
Owlet will host a conference call and webcast today, March 5, 2026, at 4:30 p.m. ET to discuss these results and provide a business update.
Participants may access the call at 833-470-1428 (domestic) or 404-975-4839 (international) and reference Access Code 211338. A simultaneous webcast may be accessed online at the Events section of Owlet’s Investor Relations website at investors.owletcare.com. A replay will be available on the Investor Relations website shortly after the webcast concludes.
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.
Owlet, Inc.
Condensed Consolidated Balance Sheets - Preliminary, Unaudited1
(in millions)
Assets
December 31, 2025
December 31, 2024
Current assets:
Cash and cash equivalents
$
35.5
$
20.2
Restricted cash
5.6
0.4
Accounts receivable, net
22.9
12.1
Inventory
15.3
10.5
Prepaid expenses and other current assets
2.7
2.8
Total current assets
$
81.9
$
46.1
Property and equipment, net
0.3
0.1
Right of use assets, net
0.1
0.1
Intangible assets, net
1.4
1.0
Other assets
2.0
2.2
Total assets
$
85.6
$
49.5
Liabilities, Mezzanine Equity, and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable
$
12.0
$
11.3
Accrued and other expenses
19.4
16.4
Current portion of deferred revenues
2.3
1.4
Line of credit
6.9
6.3
Current portion of long-term and other debt
3.6
1.1
Total current liabilities
44.2
36.4
Long-term debt, net
2.5
4.3
Common stock warrant liabilities
3.3
25.3
Other long-term liabilities
0.2
0.2
Total liabilities
50.2
66.3
Total mezzanine equity
16.4
12.9
Total stockholders’ equity (deficit)
19.0
(29.8
)
Total liabilities, mezzanine equity, and stockholders' equity (deficit)
$
85.6
$
49.5
1 Amounts may not sum due to rounding
Owlet, Inc.
Condensed Consolidated Statements of Cash Flows - Preliminary, Unaudited1
(in millions)
Year Ended December 31,
2025
2024
Net cash used in operating activities
$
(10.8
)
$
(11.2
)
Net cash used in investing activities
(0.9
)
(0.8
)
Net cash provided by financing activities
32.1
16.0
Net change in cash, cash equivalents, and restricted cash
$
20.4
$
4.1
1 Amounts may not sum due to rounding
Owlet, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - Preliminary, Unaudited1
(in millions, except share and per share amounts)
Three Months Ended
December 31,
Year Ended
December 31,
2025
2024
2025
2024
Revenues
$
26.6
$
20.5
$
105.7
$
78.1
Cost of revenues
13.9
9.5
52.2
38.7
Gross profit
12.6
11.0
53.5
39.3
Operating expenses:
General and administrative
8.7
11.8
29.2
34.0
Sales and marketing
5.2
4.0
18.5
15.8
Research and development
3.6
2.5
14.1
9.8
Total operating expenses
17.5
18.4
61.8
59.5
Operating loss
(4.9
)
(7.4
)
(8.3
)
(20.2
)
Other income (expense):
Interest expense, net
(0.6
)
(1.4
)
(3.4
)
(1.6
)
Common stock warrant liability adjustment
(2.8
)
(0.2
)
(26.6
)
9.3
Other income (expense), net
(1.0
)
—
(1.4
)
0.1
Total other income (expense), net
(4.3
)
(1.6
)
(31.4
)
7.7
Loss before income tax provision
(9.2
)
(9.0
)
(39.7
)
(12.5
)
Income tax provision
—
—
—
(0.1
)
Net loss and comprehensive loss
$
(9.2
)
$
(9.1
)
$
(39.7
)
$
(12.5
)
Accretion on convertible preferred stock
(0.8
)
(0.8
)
(3.4
)
(4.9
)
Accretion on redeemable common stock
—
—
(0.1
)
—
Allocation of net loss attributable to redeemable common stockholders
0.2
0.4
1.3
0.3
Net loss attributable to redeemable common stockholders
$
(0.2
)
$
(0.3
)
$
(1.2
)
$
(0.2
)
Net loss attributable to common stockholders
$
(9.8
)
$
(9.6
)
$
(41.9
)
$
(17.2
)
Net loss per share attributable to redeemable common stockholders
Basic and diluted
$
(0.36
)
$
(0.58
)
$
(2.16
)
$
(1.42
)
Weighted-average number of shares outstanding used to compute net loss per share attributable to redeemable common stockholders
Basic and diluted
562,500
562,500
562,500
172,131
Net loss per share attributable to common stockholders
Basic and diluted
$
(0.39
)
$
(0.63
)
$
(2.31
)
$
(1.57
)
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders
Basic and diluted
24,992,827
15,108,332
18,093,925
10,951,270
1 Amounts may not sum due to rounding
Owlet, Inc.
Reconciliation of GAAP to Non-GAAP Measures - Preliminary, Unaudited1
(in millions, except share and per share amounts)
Three Months Ended
December 31,
Year Ended
December 31,
2025
2024
2025
2024
GAAP net loss
$
(9.2
)
$
(9.1
)
$
(39.7
)
$
(12.5
)
Income tax provision
—
—
—
0.1
Interest expense, net
0.6
1.4
3.4
1.6
Depreciation and amortization
0.2
0.1
0.5
0.5
Impairment of intangible assets
—
—
—
1.9
Common stock warrant liability adjustment
2.8
0.2
26.6
(9.3
)
Stock-based compensation
4.8
1.6
9.3
8.6
Transaction costs
1.0
—
1.4
0.4
Charges related to certain legal matters, net of insurance loss recovery related to certain legal matters
—
6.2
0.3
6.2
Restructuring costs
—
—
—
0.8
Non-GAAP Adjusted EBITDA
$
0.1
$
0.5
$
2.0
$
(1.8
)
Three Months Ended
December 31,
Year Ended
December 31,
2025
2024
2025
2024
GAAP net loss
$
(9.2
)
$
(9.1
)
$
(39.7
)
$
(12.5
)
Non-GAAP adjustments:
Impairment of intangible assets
—
—
—
1.9
Common stock warrant liability adjustment
2.8
0.2
26.6
(9.3
)
Stock-based compensation
4.8
1.6
9.3
8.6
Transaction costs
1.0
—
1.4
0.4
Insurance loss recovery related to certain legal matters, net of charges related to certain legal matters
—
6.2
0.3
6.2
Restructuring costs
—
—
—
0.8
Non-GAAP adjusted net loss
$
(0.6
)
$
(1.0
)
$
(2.0
)
$
(4.0
)
Non-GAAP adjusted net loss per share
$
(0.03
)
$
(0.07
)
$
(0.11
)
$
(0.36
)
Weighted-average number of shares outstanding attributable to common stockholders, basic
24,992,827
15,108,332
18,093,925
10,951,270
1 Amounts may not sum due to rounding
View source version on businesswire.com: https://www.businesswire.com/news/home/20260305028551/en/
Owlet Media Contact:
pr@owletcare.com
Owlet Investor Contact:
ir@owletcare.com
Original: Owlet Reports Fourth Quarter and Full Year 2025 Results; Initiates 2026 Guidance
US Market News
5月前
Owlet Announces Strategic DME Partnership with PromptCare to Expand Distribution of Pediatric Pulse Oximeter, BabySat®February 11, 2026 8:46 AM
Business Wire
The partnership expands Owlet’s pediatric DME distribution footprint and supports extended commercial activation
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced a new strategic partnership with PromptCare, a leading national respiratory services and durable medical equipment (DME) provider specializing in adult and pediatric care. The partnership expands Owlet’s clinical and DME footprint across key U.S. regions and supports broader access to the Company’s FDA-cleared, prescription pulse oximeter, BabySat, through established pediatric care pathways.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211531356/en/Owlet today announced a new strategic partnership with PromptCare, a leading national respiratory services and durable medical equipment (DME) provider specializing in adult and pediatric care. The partnership expands Owlet’s clinical and DME footprint across key U.S. regions and supports broader access to the Company’s FDA-cleared, prescription pulse oximeter, BabySat, through established pediatric care pathways.
“This partnership represents a meaningful step forward in Owlet’s DME expansion strategy,” said Jonathan Harris, President and CEO of Owlet. “PromptCare’s deep experience in pediatric respiratory care and strong relationships with children’s hospitals make them an ideal partner as we continue to scale our clinical distribution model and make an impact where it matters most.”
PromptCare brings more than 40 years of experience in respiratory care delivery, operating from 25+ locations across the United States with a large, clinically trained workforce supporting pediatric and home-based care. The partnership aligns Owlet with a DME organization that already supports pediatric and respiratory care programs in children’s hospitals and healthcare systems, several of which have expressed interest in Owlet partnering with PromptCare to support their initiatives.
“Owlet’s technology complements our pediatric respiratory offerings and supports our mission to deliver high-quality, clinically relevant care in the home,” said Matt Keppler, President of Respiratory at PromptCare. “We’re excited to pilot this partnership and bring additional monitoring options to the families and providers we serve.”
The collaboration strengthens Owlet’s position within the pediatric DME channel, enhances brand legitimacy within established hospital-to-home care pathways, and expands referral opportunities for both organizations. The partnership is expected to contribute to incremental unit shipments through PromptCare as pilot programs expand.
To learn more about Owlet and its line of pediatric health monitoring devices, including BabySat and FDA-cleared Dream Sock®, please visit www.owletcare.com.
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.
About PromptCare
PromptCare is a leading national provider of in-home and alternate-site infusion therapies and high-tech, hands-on respiratory services. With 40 years of providing compassionate clinical care to patients with chronic and rare health conditions, PromptCare holds accreditations from URAC and ACHC. The company's pharmacists, respiratory therapists, nurses, and dietitians treat patients across the United States. For more information, please visit promptcare.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expectations regarding the outcomes and benefits of Owlet’s partnership with PromptCare and other third-party DME partners (including the scope, timing, and success of pilot programs and commercial activation); the Company’s ability to expand insurance-supported distribution channels, including through third-party DME partners; the availability, scope and continuity of reimbursement coverage under commercial plans, Medicaid, TRICARE and other government or private payor programs; and potential market reception and competitive positioning. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the commercial success of BabySat, related software and services, and the Company’s ability to execute and scale DME chanel initiatives, including the PromptCare partnership and any related operational, clinical workflow, or systems integrations; (ii) variability in insurance coverage, reimbursement rates, documentation requirements, clinical eligibility criteria, and payor determinations, including the risk that coverage may be reduced, delayed, denied or discontinued; (iii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and other regulatory requirements and legal proceedings; (iv) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information (including HIPAA, HITECH and comparable laws, and evolving requirements governing such activities), and risks of cybersecurity incidents or changes in applicable standards or interpretations; (v) the performance of, and Owlet’s ability to maintain and expand, its relationship with PromptCare and other third-party DME and distribution partners and other third-party technology, cloud, manufacturing and distribution partners; (vi) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vii) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, successfully execute and support integrations with third-party systems, innovate and enhance existing products, meet customer demands and adapt to changes in consumer and provider preferences and retail and healthcare trends; (viii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (ix) Owlet’s ability to maintain relationships with healthcare providers and health systems, channel partners, customers, manufacturers and suppliers; (x) impacts from compliance with applicable laws or regulations; (xi) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xii) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences, evolution of reimbursement and remote patient monitoring programs; and (xiii) Owlet’s reliance on a limited number of third-party DME, fulfillment and distribution partners for prescription-based revenue channels, and the risk that changes in those relationships, including the risk that pilot programs may not convert into broader rollouts or may be delayed due to operational, clinical, reimbursement, contracting, or payor-related factors, could adversely affect access, reimbursement or revenue growth; (xiv) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may elect to do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260211531356/en/
Owlet Media Contact:
pr@owletcare.com
Owlet Investor Contact:
ir@owletcare.com
Owlet Health Contact:
health@owletcare.com
PromptCare Contact:
hrohleder@promptcare.com
Original: Owlet Announces Strategic DME Partnership with PromptCare to Expand Distribution of Pediatric Pulse Oximeter, BabySat®
Hot Features
プレミアム
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
georgie18
2月前
harry crumb
1年前
Monksdream
2年前
glenn1919
3年前
stockchaser64
3年前
TrendTrade2016
3年前
メールアドレスで登録
